SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels. SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 167 | |
10 mg | In stock | $ 300 | |
20 mg | In stock | $ 424 | |
50 mg | In stock | $ 877 | |
100 mg | In stock | $ 1403 |
Description | SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels. SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. |
Targets&IC50 | SIRT1: 0.36 μM (EC1.5) |
CAS No. | 1001908-89-9 |
Chemical Formula | C27H24N4O2S |
Molecular Weight | 468.58 |
Solubility | DMSO: 240 mg/mL (512.2 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom